Display options
Cite
Di Bonito M, Collina F, Cantile M, et al. Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulolobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis [corrected]. J Breast Cancer. 2012;15(1):15-23doi: 10.4048/jbc.2012.15.1.15.
Di Bonito, M., Collina, F., Cantile, M., Camerlingo, R., Cerrone, M., Marra, L., Liguori, G., Pirozzi, G., & Botti, G. (2012). Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulolobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis [corrected]. Journal of breast cancer, 15(1), 15-23. https://doi.org/10.4048/jbc.2012.15.1.15
Di Bonito, Maurizio, et al. "Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulolobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis [corrected]." Journal of breast cancer vol. 15,1 (2012): 15-23. doi: https://doi.org/10.4048/jbc.2012.15.1.15
Di Bonito M, Collina F, Cantile M, Camerlingo R, Cerrone M, Marra L, Liguori G, Pirozzi G, Botti G. Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulolobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis [corrected]. J Breast Cancer. 2012 Mar;15(1):15-23. doi: 10.4048/jbc.2012.15.1.15. Epub 2012 Mar 28. PMID: 22493624; PMCID: PMC3318170.
Copy Download .nbib Format: NLM
Share it on

J Breast Cancer. 2012 Mar;15(1):15-23. doi: 10.4048/jbc.2012.15.1.15. Epub 2012 Mar 28.

Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulolobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis [corrected].

Journal of breast cancer

Maurizio Di Bonito, Francesca Collina, Monica Cantile, Rosalba Camerlingo, Margherita Cerrone, Laura Marra, Giuseppina Liguori, Giuseppe Pirozzi, Gerardo Botti

Affiliations

  1. Pathology Unit, National Cancer Institute, Pascale Hospital, Naples, Italy.

PMID: 22493624 PMCID: PMC3318170 DOI: 10.4048/jbc.2012.15.1.15

Abstract

PURPOSE: Prominin1/CD133 has become the ideal marker for cancer stem cells (CSCs) detection in human tumors. In this study we examined the expression of this marker in several breast cancer specimens to associate CSCs percentage with risk factor for this neoplasia.

METHODS: We examined specimens from 12 patients using CD133 and CD44 antibodies for CSCs immunohistochemistry detection and for flow cytometry analysis. For each patient, we also performed the immunohistochemical staining to evaluate the expression of estrogen receptor, progesterone receptor, c-erbB-2, Ki67, and E-cadherin markers. A Taqman probe for CD133 was used for mRNA quantification by real-time polymerase chain reaction.

RESULTS: Prominin-1 expression was heterogeneous in different carcinomas but was strikingly hyperexpressed in a tubulolobular variant of breast cancer. The results were confirmed by all three methods.

CONCLUSION: Our data, although produced on a limited number of samples, showed an particularly high expression of stem cell marker CD133 in a breast cancer variant, generally with a good prognosis. Since CSCs detection by CD133 has been described as an important prognostic factor for several human cancers, we suggest the importance of detecting stem cell compartiments in all histotypes of breast carcinomas.

Keywords: CD133; Neoplastic stem cells; Tubulobular breast cancer

References

  1. Breast Cancer Res. 2008;10(3):R53 - PubMed
  2. Breast Cancer Res. 2006;8(5):R59 - PubMed
  3. Oncogene. 2004 Sep 20;23(43):7274-82 - PubMed
  4. Cancer Lett. 2007 Dec 8;258(1):98-108 - PubMed
  5. J Histochem Cytochem. 2005 May;53(5):621-9 - PubMed
  6. Curr Opin Mol Ther. 2010 Dec;12(6):662-73 - PubMed
  7. Expert Opin Ther Targets. 2009 Jul;13(7):823-37 - PubMed
  8. Curr Opin Biotechnol. 2007 Oct;18(5):460-6 - PubMed
  9. Chin Med J (Engl). 2009 Nov 20;122(22):2763-9 - PubMed
  10. J Oncol. 2011;2011:135039 - PubMed
  11. Stem Cells Dev. 2009 Oct;18(8):1127-34 - PubMed
  12. Cancer Sci. 2011 May;102(5):1107-11 - PubMed
  13. Nat Rev Clin Oncol. 2011 Feb;8(2):97-106 - PubMed
  14. Stem Cells. 2003;21(4):506-8 - PubMed
  15. Stem Cells. 2008 Dec;26(12):3008-17 - PubMed
  16. Br J Cancer. 2008 Jul 8;99(1):100-9 - PubMed
  17. Exp Cell Res. 2010 May 15;316(9):1576-86 - PubMed
  18. N Engl J Med. 2006 Sep 21;355(12):1253-61 - PubMed
  19. Am J Surg Pathol. 1998 Jul;22(7):903-4 - PubMed
  20. Drug Discov Today. 2010 May;15(9-10):354-64 - PubMed
  21. Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5 - PubMed
  22. Blood. 1997 Dec 15;90(12):5013-21 - PubMed

Publication Types